Document is current

Any future updates will be listed below

Correction to: Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates

Crossref DOI link: https://doi.org/10.1007/s12325-025-03451-w

Published Online: 2025-12-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark